Last reviewed · How we verify

Indomethacin suppository

Azienda USL Reggio Emilia - IRCCS · FDA-approved active Small molecule Under review Quality 0/100

Indomethacin suppository is a Nonsteroidal anti-inflammatory drug (NSAID) Small molecule drug developed by Azienda USL Reggio Emilia - IRCCS. It is currently FDA-approved for Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis. Also known as: Indomethacin, Indocid suppository, Indocin, Indocid.

Indomethacin inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

Indomethacin suppository is a small molecule that acts as a cyclooxygenase inhibitor, which is a class of drugs that inhibit the enzyme cyclooxygenase. It has been studied for various conditions including pain, renal colic, and post-operative pancreatitis, among others.

At a glance

Generic nameIndomethacin suppository
Also known asIndomethacin, Indocid suppository, Indocin, Indocid, Indochron
SponsorAzienda USL Reggio Emilia - IRCCS
Drug classNonsteroidal anti-inflammatory drug (NSAID)
TargetCOX-1 and COX-2
ModalitySmall molecule
Therapeutic areaPain management, Rheumatology, Gastroenterology
PhaseFDA-approved

Mechanism of action

As a non-selective nonsteroidal anti-inflammatory drug (NSAID), indomethacin blocks both COX-1 and COX-2 enzymes, which are responsible for producing prostaglandins that mediate inflammatory responses, pain signaling, and fever regulation. The suppository formulation delivers the drug rectally for systemic absorption, providing anti-inflammatory and analgesic effects. This mechanism makes it effective for various inflammatory and pain conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Indomethacin suppository

What is Indomethacin suppository?

Indomethacin suppository is a Nonsteroidal anti-inflammatory drug (NSAID) drug developed by Azienda USL Reggio Emilia - IRCCS, indicated for Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis.

How does Indomethacin suppository work?

Indomethacin inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

What is Indomethacin suppository used for?

Indomethacin suppository is indicated for Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Acute pain and inflammation, Patent ductus arteriosus (in neonates).

Who makes Indomethacin suppository?

Indomethacin suppository is developed and marketed by Azienda USL Reggio Emilia - IRCCS (see full Azienda USL Reggio Emilia - IRCCS pipeline at /company/azienda-usl-reggio-emilia-irccs).

Is Indomethacin suppository also known as anything else?

Indomethacin suppository is also known as Indomethacin, Indocid suppository, Indocin, Indocid, Indochron.

What drug class is Indomethacin suppository in?

Indomethacin suppository belongs to the Nonsteroidal anti-inflammatory drug (NSAID) class. See all Nonsteroidal anti-inflammatory drug (NSAID) drugs at /class/nonsteroidal-anti-inflammatory-drug-nsaid.

What development phase is Indomethacin suppository in?

Indomethacin suppository is FDA-approved (marketed).

What are the side effects of Indomethacin suppository?

Common side effects of Indomethacin suppository include Gastrointestinal irritation or ulceration, Dyspepsia, Headache, Dizziness, Nausea, Rectal irritation (suppository formulation).

What does Indomethacin suppository target?

Indomethacin suppository targets COX-1 and COX-2 and is a Nonsteroidal anti-inflammatory drug (NSAID).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing